Crescita Therapeutics (Crescita Therapeutics) Loans Receivable : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Crescita Therapeutics Loans Receivable?

Crescita Therapeutics's Loans Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.

Crescita Therapeutics Loans Receivable Historical Data

The historical data trend for Crescita Therapeutics's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crescita Therapeutics Loans Receivable Chart

Crescita Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Loans Receivable

Get a 7-Day Free Trial

Crescita Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Loans Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Crescita Therapeutics Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Crescita Therapeutics Loans Receivable Related Terms

Thank you for viewing the detailed overview of Crescita Therapeutics's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Crescita Therapeutics (Crescita Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Crescita Therapeutics Inc (OTCPK:CRRTF) » Definitions » Loans Receivable

Comparable Companies

Traded in Other Exchanges

CTX:Canada

Address

2805, Place Louis-R-Renaud, Laval, QC, CAN, H7V 0A3

Website

https://www.crescitatherapeutics.com

Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue in the form of product sales and out-licensing revenue.